Nuclear medicine imaging was born over 60 years ago with imaging of thyroid conditions. Most of our present imaging devices were developed for imaging of the thyroid and thyroid cancer. Millions of patients in over 100 countries have been diagnosed and treated for thyroid cancer using nuclear medicine techniques. It remains, however, one of the most dynamic areas of development in nuclear medicine with new roles for positron emission tomography and receptor based imaging. In addition to this is research into combinations of genetic therapy and radioisotopes and receptor based therapy using beta emitting analogues of somatostatin. Despite the use of ultrasound computed tomography and magnetic resonance, nuclear medicine techniques remain central to both imaging and therapy in thyroid disease and the field has recently become one of the most dynamic within the specialty.
Introduction
Differentiated thyroid cancer (DTC), though not the commonest of cancers, remains one of the cancers that we are keen to identify, stage and treat as even in its most advanced state cures though unlikely are possible. A range of radiopharmaceuticals have been used in the management of thyroid cancer over the past 60 years (Table 1 ) and in this review their present usage is assessed.
The initial diagnosis of thyroid cancer can be made by a combination of clinical history, palpation and ultrasound; fine needle aspiration nuclear imaging may be used but under present guidelines thyroid scintigraphy is not indicated as a primary investigation of suspected thyroid cancer [1] . However, most large centres performing isotopic thyroid studies will find 12 incidental thyroid cancers a year on the pre-treatment scan performed on patients with hyperthyroidism using 123 I or 99m Tc pertechnetate. These cancers will appear as a cold nodule but this appearance is very non-specific ( Fig. 1) . A cold nodule on a functional thyroid scan is normally benign with reported rates of malignancy varying from 5 to 20% [24] . So whilst it requires further investigation often ultrasound will suffice as these cold nodules are normally cysts.
The next major role of nuclear medicine has been after surgery with whole body imaging and post surgery ablation of thyroid tissue with 131 I. This often seems a paradox. How is it that thyroid cancer is negative on a diagnostic thyroid cell but positive on a whole body 131 I scan? The reason is that the whole body 131 I images are performed 4872 h after administration of the radiotracer allowing cells with poor uptake, e.g. cancer cells enough time to accumulate the radioiodine. When performing local imaging, the non-cancerous normal thyroid cells take up the radioiodine or pertechnetate at a much higher rate so the cancer appears as a defect.
I whole body imaging
The standard methods for imaging patients with differentiated thyroid cancer is to perform whole body imaging with 131 I. This has normally been done with a small tracer dose of about 150185 MBq of 131 I given orally and then imaged 4872 h later. To ensure good uptake of the 131 I the patient should be prepared by withdrawal of thyroid replacement therapy (4 weeks is required for thyroxine) and the patient is often asked to take a low iodine diet avoiding fish and other sea foods. The count rates obtained from 131 I imaging are often poor and images less than ideal quality. This is partly due to the fact that 131 I gives off a variety of different gamma rays with different energies resulting in scatter but the high energy gamma photons up to 580 keV need a high energy collimator which blocks about 95% of the counts coming from the patient. In such circumstance the administered activity of the radiopharmaceutical would be increased however, it is normal practice when there is any evidence of residual thyroid tissue or cancer to give a therapeutic dose of 131 I within 23 days. This is done so that the patient does not need to withdraw from thyroid replacement again. There is now clear evidence that administration of too high an activity of 131 I given for imaging damages the thyroid cancer cells in such away that they have reduced uptake of the therapeutic dose of 131 I in up to 80% of cases; a process known as stunning [5, 6] . There is some evidence that stunning may occur with activities of 131 I as low as 74 MBq at which point image quality is very poor [7] . An alternative approach has been to assume that all patients post thyroidectomy will need 131 I ablation and plan to give a 3 GBq ablative activity 6 weeks after surgery (Figs. 2 and 3 ) withdrawing lio-thyronine 2 weeks before therapy. If there is no uptake on the post therapy scan no more 131 I is given; however, if there is activity then treatment with 5 GBq of 131 I is given until the post therapy scan is clear [8] . Whilst there is some concern that the patient may receive an unnecessary radiation dose, it has also been suggested that a dose of 131 I given when the subsequent scan is negative may be treating sub-1 cm tumours not visible on the scan [9] . Once the patient is ablated they can be followed by plasma levels of thyroglobulin.
Other imaging modalities that can be used include chest X-ray, and computed tomography (CT) of neck, chest and abdomen which must be performed without contrast so is of limited use. There is at present no consensus on when and how newer contrast agents with faster clearance can be used. In addition, magnetic resonance imaging (MRI) of neck, spin and liver and ultrasound of liver and neck and bone scintigraphy are often performed. These other techniques tend to be used when there is evidence of disease not seen on the 131 I scan or confirm the site of abnormality seen on the 131 I scan.
Ablative therapy
The aim of ablative therapy is to remove all thyroidal tissue both benign and malignant so that the patient can be followed by serial plasma thyroglobulin levels. Data from over 40 years show that in all but stage 1 tumours there is a progression and overall survival benefit from ablation but this is only apparent 1025 years after surgery [10] . There is, however, some discussion on the activity of 131 I needed for ablation with some observers stating that this could be achieved with activities much lower than the standard 3 GBq [11] . To attempt to answer this question, the British National Cancer Research Network (NCRN) Head and Neck group have facilitated a national prospective randomized controlled trial comparing high and low activity ablative doses of 131 I. It is hoped that this study called the HiLo study will report in 20092010.
Recombinant TSH/transgenic changes
To ensure adequate uptake of 131 I into tumour cells that often have reduced iodine trapping it is necessary to remove any competition for the cell membrane sodium iodide symporter (NIS). Some variants such as Hurtle cell tumour have poor uptake of radioiodine in almost all cases. Therefore excess iodine (the most common source being CT contrast) should be avoided for at least 6 months. In addition the cells need to be stimulated by high levels of thyroid stimulating hormone (TSH) The normal method to do this and obviously the cheapest is withdrawal of thyroid replacement therapy started after thyroidectomy for at least 4 weeks. Though it may be possible to cover the first 2 weeks of this withdrawal with lio-thyronine, the aim of the exercise is to make the patient profoundly hypothyroid. This can be very unpleasant and for the more elderly patient with cardiac disease it can lead to a significant cardiac event [12] . Uptake of 131 I can also be assisted by administration of thyrotrophin releasing hormone (TRH) which induces additional TSH release from the pituitary 3060 min before giving the 131 I [13] . More recently recombinant human TSH (rhTSH) has become available and pre-administration 48 and 24 h before giving the radiotracer can result in similar uptake of 131 I into the tumour tissues as 4 weeks of thyroxine withdrawal [14, 15] . There are clear advantages that the patient does not have to have the symptoms of hypothyroidism or the cardiac risks. The only significant drawback is that the treatment costs about £1000 (E1500).
In some patients there may be very poor or little uptake of radioiodine. This could be because the cells no longer express the NIS gene. This is probably a defensive mechanism for cells exposed to non-lethal levels of radioiodine and those that survive may be those that do not take up the radioactive tracer [16] . There is some evidence, however, that the NIS gene expression can be stimulated by pre-medication with lithium or retinoids [13, 17, 18] but so far there remains no clear consensus on their use and they have not entered general usage. In addition to this, there is some interesting pre-clinical work looking at viral vectors to try and re-transfect these cells with the NIS gene [19] . Whether or not any of this technology will find a clinical role remains unclear. In addition, the use of NIS gene transfection may in itself increase tumour retention of 131 I and this requires organification which is controlled by a different gene.
I
As the main role for whole body imaging is to determine if there is sufficient thyroid tissue to need further ablation by 131 I, it may be possible to use an isotope of iodine without beta emission and therefore reduce the risk of blunting.
123 I, a cyclotron produced isotope of iodine with a 13-h half life and a pure gamma emission photon of 167 keV has been used for thyroid imaging for over 25 years. However, recently it has also been introduced for whole body imaging [20] . As there are no beta or high energy gamma emissions, there is improved dosimetry, which means that sufficient 123 I (about 100 MBq) can be administered to ensure a good count rate at 24 h. This can improve image quality as well as prevent stunning. [21] . The disadvantage is cost as 123 I is up to 5 times greater in price than 131 I.
Positron emission tomography (PET)
Despite the advances in imaging that are obtained with use of 123 I, there will be a cohort of patients in whom there is biochemical evidence of residual thyroid cancer by a raised and rising thyroglobulin level but no active disease can be found by 131 [22] . The use of rhTSH pre [ 18 F]FDG PET is being investigated [23] . Using PET-CT it is possible to not only identify any abnormal sites of activity suggestive of metastatic disease but to localize the site of any abnormality which will aid biopsy, surgery or radiotherapy and these tumours tend to be chemo-resistant and only local treatments are effective. Though few studies have been performed, the accuracy of [ 18 F]FDG in thyroid cancer is as high as 95% and in particular for those tumours that have de-differentiated and are therefore 123 I/ 131 I negative [2428] . Incidentally, [
18 F]FDG PET-CT can also be used in anaplastic thyroid cancer but its clinical utility is doubtful in view of the dismal prognosis of the anaplastic variant. It may also be possible to use 124 I, a positron emitter, but there is as yet little evidence that this is not just a more expensive way to image with radioiodine and no clear clinical advantage has been shown [29] . A footnote to the [ 18 F]FDG PET story in thyroid cancer is that both benign and malignant growths can be very glucose avid. As a consequence as more patients undergo [
18 F]FDG imaging for other disease, serendipitous uptake in the thyroid may be seen (Fig. 4) . These should be investigated. It is difficult to know how many such nodules are seen on PET but last year we found 2 previously unknown thyroid cancers in the 500 patients we sent for [ 18 F]FDG PET imaging so a big centre performing 2500 PET scans a year can expect to find approximately 10 previously unknown thyroid cancers. In addition to this will be the occasional cancer metastases in the thyroid and thyroid lymphoma. All this means that all sites of unexpected thyroid uptake of [
18 F]FDG must be fully investigated.
Metabolic imaging single photon
Though PET imaging provides probably the best functional imaging modality to assess cancer patients, there are still significant issues related to access and cost of these techniques. Therefore other simple single photons techniques have been developed and used historically in assessment of thyroid cancers. As thyroid cancers tend to have a higher metabolic turnover than normal tissues tracers such as [ Tc]sestamibi, the chance of malignancy rises from 5% to 60% [3032] . Also it was used in finding tumours in the scenario of raised thyroglobulin and negative 131 I scan but has really been superseded by PET techniques.
There may still, however. be a role for 67 Ga citrate in identification of thyroid lymphoma where diffuse uptake throughout the gland is diagnostic, though this is more likely to be a finding in a patient imaged for another reason such as fever of unknown cause.
Somatostatin imaging
Somatostatin analogues such as octreotide have been used to treat the symptoms of neuroendocrine tumours for 15 years and a radiolabelled form, [
111 In]pentetreotide has been used for imaging of neuroendocrine tumours such as carcinoid [33] . However, it was found that there was uptake in a range of other cancers which had expression of the sub-type-2 receptor for which pentetreotide has a very high affinity. (Fig. 5 ) [34, 35] . This was found to be true for those tumours with and without uptake of 131 I so could be used as an alternative to [ 18 F]FDG PET imaging. There are, however, disadvantages in using somatostatin imaging in that uptake depends on receptor expression; the resolution is not as good as PET and the cost can be higher.
In patients in whom there is known to be tumour and in whom there is no evidence for uptake of 131 I, a positive [
111 In]pentetreotide scan may mean the possibility of treatment with 90 Y-or 177 Lu-labelled somatostatin analogues. These products are not commercially available but have been used in a variety of European centres where it can be manufactured on site. Some early work in thyroid cancer has produced encouraging results [36, 37] .
MCT
Medullary cell cancer of the thyroid (MCT) is a cancer of the calcitonin producing cells in the thyroid. These cells do not have an iodine uptake mechanism and therefore imaging with radioiodine or pertechnetate and treatment with 131 I will not work. However, the tumour is a neuroendocrine tumour. Imaging can be performed with [
111 In]pentetreotide with good results (Fig. 5 ) [38] . Also it is possible to use the amine uptake mechanism used by meta-iodobenzyl guanidine (mIBG). This seems to have uptake in about 60% of patients with MCT and, like [
111 In]pentetreotide, can be used for staging local disease and metastases [39] . Whole body imaging with SPECT of the neck is used with both of these agents, with additional SPECT as required. An added advantage of 123 I mIBG imaging is that in patients with multiple endocrine neoplasia type 2 (MEN2), any co-incidental phaeochromocytoma may be found.
The prime role of these agents, however, is not just staging but to determine if therapy can be undertaken with beta labelled versions of these agents, either 90 Y-labelled somatostatin analogues (Fig. 7) or 131 Ilabelled mIBG [40, 41] . Imaging alone has been shown to be effective with [ 99m Tc]pentavalent dimercapto succinic acid (DMSA(V)) [42] . The advantage is that there is a high sensitivity of greater than 90% especially for nodal disease. Also unlike somatostatin receptor and mIBG imaging, it can be positive in tumours that do not display the correct receptors. A therapeutic version of (DMSA(V)) using 186 Re or 188 Re is under development [43] . [ 18 F]FDG PET-CT has been used increasingly in metastatic MCT but at present there is insufficient data to state if it will be used instead of the established nuclear medicine techniques.
Conclusions
For the past 60 years nuclear medicine has been at the heart of diagnosis and treatment of patients with thyroid cancers. Methods of imaging have been refined as have optimal protocols for therapy. Newer techniques such as PET and receptor based imaging and therapy has meant that this oldest branch of nuclear medicine has also become one of its fastest moving. 
